Market Overview

Benzinga's Top Upgrades

Related CAH
Benzinga's Top Downgrades
Analyst: Cardinal Health Buying Spree To Boost FY17 EPS
13 Dividend Stocks Passing Rigorous Quality, Growth And Valuation Filter Criteria (Seeking Alpha)
Related LLY
Lilly Receives FDA Breakthrough Therapy Designation for Abemaciclib - a CDK 4 and 6 Inhibitor - in Advanced Breast Cancer
10 Defensive Stock Ideas From Bank Of America
Eli Lilly's abemaciclib a Breakthrough Therapy for certain type of breast cancer (Seeking Alpha)

Analysts at ISI Group upgraded Cardinal Health (NYSE: CAH) from “hold” to “buy.” Cardinal Health's shares closed at $40.85 yesterday. Cardinal Health's trailing-twelve-month ROE is 17.70%.

Analysts at Goldman Sachs upgraded Eli Lilly & Co (NYSE: LLY) from “sell” to “neutral.” Eli Lilly's shares closed at $50.78 yesterday. Eli Lilly's trailing-twelve-month revenue is $23.40 billion.

Analysts at Citigroup upgraded The Interpublic Group of Companies (NYSE: IPG) from “neutral” to “buy.” Interpublic Group's stock closed at $11.43 yesterday. Interpublic Group's PEG ratio is 1.16.

Analysts at Sterne Agee upgraded Shoe Carnival (NASDAQ: SCVL) from “neutral” to “buy.” Shoe Carnival's shares closed at $22.65 yesterday. Shoe Carnival's trailing-twelve-month operating margin is 5.61%.

Latest Ratings for CAH

Jul 2015Evercore ISIDowngradesBuyHold
Jun 2015Deutsche BankMaintainsHold
Mar 2015FBR CapitalMaintainsOutperform

View More Analyst Ratings for CAH
View the Latest Analyst Ratings

Posted-In: top upgradesUpgrades Analyst Ratings


Related Articles (CAH + IPG)

Get Benzinga's Newsletters